This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (8)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Public Health  • Substance Abuse/ Alcoholism  • Randomized Controlled Trial  • Alert me on articles by topic

A Randomized Controlled Trial

Lisa A. Marsch, PhD; Warren K. Bickel, PhD; Gary J. Badger, MS; Marne E. Stothart, MA; Kimberly J. Quesnel, MSW; Catherine Stanger, PhD; John Brooklyn, MD

Arch Gen Psychiatry. 2005;62:1157-1164.

Context  The prevalence of heroin and other opioid use has markedly increased among adolescents in the last decade; however, virtually no research has been conducted to identify effective treatments for this population.

Objective  To evaluate the relative efficacy of 2 pharmacotherapies, the partial opioid agonist buprenorphine hydrochloride and the centrally active ₂-adrenergic blocker clonidine hydrochloride, in the detoxification of opioid-dependent adolescents.

Design, Setting, and Patients  A double-blind, double-dummy, parallel-groups randomized controlled trial conducted in a university-based research clinic from October 2001 to December 2003. Patients were a volunteer sample of 36 adolescents who met DSM-IV criteria for opioid dependence (ages 13-18 years eligible).

Interventions  Participants were randomly assigned to a 28-day, outpatient, medication-assisted withdrawal treatment with either buprenorphine or clonidine. Both medications were provided along with thrice weekly behavioral counseling and incentives contingent on opiate abstinence. Postdetoxification, all participants were offered the opportunity for continued treatment with the opiate antagonist, naltrexone hydrochloride.

Main Outcome Measures  Treatment retention, opiate abstinence, and human immunodeficiency virus risk behavior, along with measures of withdrawal and medication effects.

Results  A significantly greater percentage of adolescents who received buprenorphine were retained in treatment (72%) relative to those who received clonidine (39%) (P<.05). For those in the buprenorphine group, a significantly higher percentage of scheduled urine test results were opiate negative (64% vs 32%; P = .01). Participants in both groups reported relief of withdrawal symptoms and drug-related human immunodeficiency virus risk behavior. Those in the buprenorphine condition generally reported more positive effects of the medication. No evidence of opioid intoxication or psychomotor impairment was observed. Sixty-one percent of participants in the buprenorphine condition and 5% of those in the clonidine group initiated treatment with naltrexone.

Conclusion  Combining buprenorphine with behavioral interventions is significantly more efficacious in the treatment of opioid-dependent adolescents relative to combining clonidine and behavioral interventions.

Author Affiliations: Departments of Psychiatry (Drs Marsch, Bickel, Stanger, and Brooklyn and Mss Stothart and Quesnel) and Medical Biostatistics (Mr Badger), University of Vermont, Burlington. Dr Marsch is now with National Development and Research Institutes and St Luke’s-Roosevelt Hospital Center, New York, NY. Dr Bickel is now with the University of Arkansas for Medical Sciences, Little Rock.

RELATED ARTICLE

Adolescent Opioid Abuse
Charles P. O’Brien
Arch Gen Psychiatry. 2005;62(10):1165.
EXTRACT | FULL TEXT